We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer's Aliqopa Meets Primary Endpoint in Lymphoma Study
Read MoreHide Full Article
Bayer AG (BAYRY - Free Report) announced that the phase III study, CHRONOS-3, evaluating Aliqopa (copanlisib) in combination with Roche’s (RHHBY - Free Report) Rituxan (rituximab) in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL), met its primary endpoint of significantly prolonging progression-free survival (PFS). Non-Hodgkin’s lymphoma (NHL) comprises a highly heterogeneous group of chronic diseases with poor prognosis. Histological subtypes included in the study were follicular lymphoma (FL), small lymphocytic lymphoma (SLL), lymphoplasmacytoid lymphoma/Waldenstrom macroglobulinemia (LPL/WM) and marginal zone lymphoma (MZL).
Shares of Bayer have declined 36.1% year to date against the industry’s 0.8% decline.
Aliqopa is a pan class I- phosphatidylinositol-3-kinase (PI3K) inhibitor, with predominant activity against the PI3K-alpha and PI3K-delta isoforms expressed in malignant B-cells.It is approved by the FDA under accelerated approval for the treatment of adult patients experiencing relapsed FLwho have received at least two prior systemic therapies. The approval was based on the phase II CHRONOS-1 study.
CHRONOS-3 is a phase III study with the objective to evaluate whether Aliqopa in combination with Rituxan is superior to placebo plus Rituxan in extending PFS in patients with relapsed iNHL. Patients were randomized at a 2:1 ratio. Safety and tolerability observed in the study were generally consistent with the previously published data on the individual components of the combination and no new safety signals were identified.
We remind investors that Bristol-Myers Squibb’s (BMY - Free Report) Revlimid (lenalidomide) in combination with a rituximab product (R²) is approved in the United States for the treatment of adult patients with previously treated FL or MZL. This is the first combination regimen for patients with these indolent forms of NHL that do not include chemotherapy.
Emergent’s earnings estimates have increased from $4.03 to $6.61 for 2020 and from $5.07 to $8.42 for 2021 over the past 90 days. Shares of the company have increased 81.2% year to date.
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Bayer's Aliqopa Meets Primary Endpoint in Lymphoma Study
Bayer AG (BAYRY - Free Report) announced that the phase III study, CHRONOS-3, evaluating Aliqopa (copanlisib) in combination with Roche’s (RHHBY - Free Report) Rituxan (rituximab) in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL), met its primary endpoint of significantly prolonging progression-free survival (PFS). Non-Hodgkin’s lymphoma (NHL) comprises a highly heterogeneous group of chronic diseases with poor prognosis. Histological subtypes included in the study were follicular lymphoma (FL), small lymphocytic lymphoma (SLL), lymphoplasmacytoid lymphoma/Waldenstrom macroglobulinemia (LPL/WM) and marginal zone lymphoma (MZL).
Shares of Bayer have declined 36.1% year to date against the industry’s 0.8% decline.
Aliqopa is a pan class I- phosphatidylinositol-3-kinase (PI3K) inhibitor, with predominant activity against the PI3K-alpha and PI3K-delta isoforms expressed in malignant B-cells.It is approved by the FDA under accelerated approval for the treatment of adult patients experiencing relapsed FLwho have received at least two prior systemic therapies. The approval was based on the phase II CHRONOS-1 study.
CHRONOS-3 is a phase III study with the objective to evaluate whether Aliqopa in combination with Rituxan is superior to placebo plus Rituxan in extending PFS in patients with relapsed iNHL. Patients were randomized at a 2:1 ratio. Safety and tolerability observed in the study were generally consistent with the previously published data on the individual components of the combination and no new safety signals were identified.
We remind investors that Bristol-Myers Squibb’s (BMY - Free Report) Revlimid (lenalidomide) in combination with a rituximab product (R²) is approved in the United States for the treatment of adult patients with previously treated FL or MZL. This is the first combination regimen for patients with these indolent forms of NHL that do not include chemotherapy.
Zacks Rank and A Stock to Consider
Bayer currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the healthcare sector includes Emergent Biosolutions Inc. (EBS - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $4.03 to $6.61 for 2020 and from $5.07 to $8.42 for 2021 over the past 90 days. Shares of the company have increased 81.2% year to date.
Bayer Aktiengesellschaft Price
Bayer Aktiengesellschaft price | Bayer Aktiengesellschaft Quote
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>